Company intelligence / Profile preview

Kinovate Life Sciences

Oceanside, California, United Stateskinovate.com ↗

Ownership: Private
Employees: ~30
Development stage: Other

Overview

Kinovate Life Sciences supplies high-performance polymeric solid supports—NittoPhase™ and NittoPhase™ HL—for the synthesis of therapeutic oligonucleotides. Their products are widely adopted in clinical and commercial programs globally due to their quality, scalability, and regulatory compliance. The company does not have its own drug candidates or clinical results but enables the development of RNA/DNA-based therapies by pharmaceutical partners.

No direct pipeline or proprietary therapeutics.

Therapeutic areas: Other
Modalities: OligonucleotidePolymer-based solid support
Industry: Chemicals & Materials

Partnerships

Isis Pharmaceuticals/Ionis Pharmaceuticals (collaborative development/optimization of solid support technology; Isis receives royalties on sales)

Beyond the preview

Go deeper on Kinovate Life Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kinovate Life Sciences.

Explore the full profile